Poor
Poor alignment
Patient Risk:
Low
Summary
The AI-generated claims are not supported by the provided FDA label; all seven claims are absent from the labeling.
Category Scores
Accurate Statements
Unsupported Statements
Leuprolide acetate injectable suspensions (the generic form) are available in the US.
Not supported by FDA label; label does not assert generic availability.
Generics cover many of the same depot formulations used for the brand products (Lupron/Lupron Depot).
Not supported by label; no label content about generic equivalence.
Availability can vary by dose.
Not supported by label; no label content about dose-based availability.
Availability can vary by pharmacy.
Not supported by label; no label content about pharmacy-based availability.
Availability can vary by insurer.
Not supported by label; no label content about insurer-based availability.
Some brand formats (for example, certain long-acting autoinjector versions) may not have a generic equivalent.
Not supported by label; no label content about generic equivalents for brand formats.
The FDA Orange Book lists current generic approvals and NDCs.
Not supported by label; label does not reference FDA Orange Book.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claims evaluated relate to availability and generics and do not present safety risks.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Poor alignment
Primary Issue
Claims about generic availability, cross-brand equivalence, and Orange Book references are not supported by the FDA label.
Suggested Improvement
Limit statements to content supported by the label (indication, dosing, contraindications, warnings, adverse reactions, etc.). If evaluating label accuracy, verify each factual claim directly against the prescribing information and avoid non-label references or general market information.